AbSci to Present at the 39th Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash., Jan. 7, 2021 /PRNewswire/ — AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain, Founder and CEO, will present virtually at the 39th...AbSci Announces Recent Additions to Board of Directors
Ivana Magovčević-Liebisch, Ph.D., J.D. and Karen McGinnis join AbSci Board as Independent Directors VANCOUVER, Wash., Nov. 11, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost...AbSci Announces $65 Million Financing Led by Casdin Capital
Financing to accelerate first mover advantage of Protein Printing™ technology which enables revolutionary efficiencies in protein manufacturing VANCOUVER, Wash., Oct. 20, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™...Alpha Cancer Technologies to License AbSci’s SoluPro Strain for the Expression of Alpha-Fetoprotein
Igor Sherman, CEO of Alpha Cancer Technologies comments, “Many have tried using conventional expression platforms and have been unsuccessful. This is a truly enabling platform that provides an expanded commercialization pathway for ACT and will allow us to significantly expand our patent life and IP portfolio”